Form 8-K - Current report:
SEC Accession No. 0001739410-25-000100
Filing Date
2025-07-08
Accepted
2025-07-08 08:08:55
Documents
13
Period of Report
2025-07-08
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.01: Completion of Acquisition or Disposition of Assets
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K rlyb-20250708.htm   iXBRL 8-K 31970
2 EX-99.1 rlyb-20250708xex.htm EX-99.1 13025
  Complete submission text file 0001739410-25-000100.txt   173752

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT rlyb-20250708.xsd EX-101.SCH 1773
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT rlyb-20250708_lab.xml EX-101.LAB 23449
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT rlyb-20250708_pre.xml EX-101.PRE 13575
15 EXTRACTED XBRL INSTANCE DOCUMENT rlyb-20250708_htm.xml XML 2917
Mailing Address 234 CHURCH STREET SUITE 1020 NEW HAVEN CT 06510
Business Address 234 CHURCH STREET SUITE 1020 NEW HAVEN CT 06510 203- 859-3820
Rallybio Corp (Filer) CIK: 0001739410 (see all company filings)

EIN.: 851083789 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40693 | Film No.: 251109554
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)